Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
358
datasets available to search
ShareScore release 0.9.0
Dataset results
358 results for “SAR studies”
Dataset: Elisa cohort study on SARS-CoV-2 transmission
<p>The Elisa study is a population-based cohort study in Lübeck and the surrounding area (northern Germany) with the aim to determine the prevalence and influencing factors of infections with the Sars-CoV2 over a one-year period. The study collected data from April 2020 to February 2021. A cohort of 3000 randomly selected individuals were screened by swab (PCR) for active corona infection and blood draws were performed to determine antibodies at seven time points. In addition, continuous app-based questionnaires were administered to study participants regarding symptoms, behavior, and social factors.</p> <p>The data set consists of a file with baseline variables and examination results for the 3000 participants and another file with the continuous survey data (90,000 interviews).</p>
Figures S1–S10 from: Shoman ME, Abd El-Hafeez AA, Khobrani M, Assiri AA, Al Thagfan SS, Othman EM, Ibrahim ARN (2022) Molecular docking and dynamic simulations study for repurposing of multitarget coumarins against SARS-CoV-2 main protease, papain-like protease and RNA-dependent RNA polymerase. Pharmacia 69(1): 211-226. https://doi.org/10.3897/pharmacia.69.e77021
Molecular docking and Dynamic simulations study for repurposing of multitarget Coumarins against SARS-CoV-2 main protease, papain like protease and RNA-Dependent RNA polymerase.
Longitudinal Assessment of TCR Repertoires in Recipients of Inactivated SARS-CoV-2 Vaccines: An Artificial Intelligence-Guided Study
<p>T cells play a crucial role in mitigating disease severity during SARS-CoV-2 infection and in shaping long-term immune memory. However, the precise molecular immune response involving T-cell receptor (TCR) repertoire changes following full vaccination, and evaluating vaccine efficacy through TCR analysis, remains incompletely understood. In this study, we conducted a 10-month longitudinal investigation of individuals who received SARS-CoV-2 inactivated vaccines and developed a vaccine efficacy evaluation model. Through the advanced large language artificial intelligence method, we identified vaccine-specific TCR clones, 3 V genes, 20 V-J combinations, and 3 epitopes, and traced their longitudinal development. The vaccine-specific TCR clones expanded to peak levels after the second vaccine dose and remained detectable in most subjects at 10 months. Utilizing vaccine-specific TCRs as novel markers, we constructed a vaccine efficacy evaluation model that predicts antibody levels with a mean AUC of 0.96, highlighting the relationship between vaccine-specific TCRs and antibodies. Our findings reveal the longitudinal patterns of vaccine-specific TCR clones and the potential of the efficacy evaluation model built upon them.</p>
Positive selection screen in yeast for inhibitors of SARS-CoV-2 Main Protease. Dataset from docking studies.
<p>Best docked poses from XP docking and covalent docking (Glide; Schrödinger 2021-2) towards the SARS-CoV-2 MPro protein (PDB ID 7CB7). List of ligands is also included. </p>
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
ClinicalTrials.gov study NCT04325646. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study
ClinicalTrials.gov study NCT04340466. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
ClinicalTrials.gov study NCT04818281. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
ClinicalTrials.gov study NCT05897541. IPD Sharing: NO. Countries: 5. Publications: 0.
Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)
ClinicalTrials.gov study NCT05033145. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
ClinicalTrials.gov study NCT04611802. IPD Sharing: NO. Countries: 3. Publications: 7.
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
ClinicalTrials.gov study NCT04743388. IPD Sharing: NO. Countries: 1. Publications: 4.
B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency
ClinicalTrials.gov study NCT04954469. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
ClinicalTrials.gov study NCT04494776. IPD Sharing: NO. Countries: 1. Publications: 7.
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.
ClinicalTrials.gov study NCT04347694. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
ClinicalTrials.gov study NCT04750343. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
ClinicalTrials.gov study NCT06039449. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study)
ClinicalTrials.gov study NCT05128760. IPD Sharing: YES. Countries: 1. Publications: 4.
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection
ClinicalTrials.gov study NCT04750720. IPD Sharing: Not stated. Countries: 1. Publications: 6.
COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)
ClinicalTrials.gov study NCT04637867. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
ClinicalTrials.gov study NCT05007509. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.